Quarterly report · Q2
9989.TEDINET S100SAP5
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥371.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥690.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥339.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥18.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥21.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥38.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥18.5bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.7bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥12.7bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥369.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥360.7bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥337.1bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥125.2bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥124.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥244.7bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥236.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥229.1bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥76.8bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥80.9bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥76.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥80.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥94.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥89.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥23.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥37.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥21.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥28.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥120.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.18 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥219.83 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.81 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥219.82 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥108.81 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 66.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥26.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥26.1bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥155.0bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥155.0bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥7.5bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥242.8bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥216.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥26.1bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥397.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥371.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥26.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥20.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥24.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥24.7bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥143.9bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥143.9bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥220.0bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥195.3bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥24.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥11.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥363.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥339.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥24.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥18.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 479
| Item | Context | Value | Unit |
|---|---|---|---|
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社サンドラッグ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都府中市若松町一丁目38番地の１ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |